Solar Pharma to conduct scientific trial of pancreatitis drug in Covid-19 sufferers – india information


Drugmaker Solar Pharmaceutical Industries Ltd mentioned on Friday that it acquired Indian regulatory approval to begin scientific trials of pancreatitis drug nafamostat mesilate in COVID-19 sufferers.


“Nafamostat (has been) recognized as a possible candidate for COVID-19 sufferers by scientists at College of Tokyo and Leibniz Institute for Primate Analysis, Germany,” the corporate mentioned in an announcement

The College of Tokyo had introduced plans for a trial of nafamostat and camostat mesilate, a associated drug, beginning as early as April 2020.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Translate »